Activist Investor Oramed Pharmaceuticals Increases Stake in Nano Dimension, Reiterates Dissatisfaction
NNDM sits 57% above its 52-week low of $1.31.
Summary
Oramed Pharmaceuticals, an activist investor, has increased its stake in Nano Dimension to 5.2% through additional share purchases and reiterated its intent to engage with management regarding performance and governance.
Key Events · Ownership and Investor Activity · NNDM
-
Increased Stake
Oramed Pharmaceuticals increased its beneficial ownership in Nano Dimension to 5.2% of outstanding shares.
-
Additional Share Purchases
Oramed acquired an additional 1,425,000 ordinary shares for approximately $2.8 million in open market transactions on February 17-18, 2026.
-
Reiterated Activist Intent
Oramed communicated its dissatisfaction with Nano Dimension's management and expressed intent to further engage on performance, strategic direction, shareholder value, and governance.
-
Follows Poison Pill Adoption
This filing follows Nano Dimension's adoption of a shareholder rights agreement (poison pill) on February 3, 2026, indicating continued pressure from the activist investor.
Analysis · NNDM · Manufacturing
This amended Schedule 13D reveals Oramed Pharmaceuticals' continued aggressive stance towards Nano Dimension. Following Nano Dimension's adoption of a poison pill, Oramed has not only increased its beneficial ownership to 5.2% through recent open market purchases totaling approximately $2.8 million but has also explicitly communicated its dissatisfaction with management and intent to further engage on strategic direction and governance. This signals a deepening activist battle, indicating Oramed is not deterred by the defensive measures and plans to continue pressing for changes. Investors should anticipate ongoing corporate governance discussions and potential proxy contests.
At the time of this filing, NNDM was trading at $2.06 on NASDAQ in the Manufacturing sector, with a market capitalization of approximately $433.9M. The 52-week trading range was $1.31 to $2.44. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.